Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01034553 · ClinicalTrials.gov registry record · Phase 1
Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01034553: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01034553 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01034553, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
RATIONALE: Aurora A kinase inhibitor MLN8237 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving aurora A kinase inhibitor MLN8237 together with bortezomib and to see how well they work in treating patients with relapsed or refractory multiple myeloma.
Interventions
- DRUG bortezomib
- DRUG Aurora A kinase inhibitor MLN8237
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2010-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01034553
The ClinicalTrials.gov registry entry for NCT01034553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which bortezomib is the first listed.
NCT01034553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01034553 about?
NCT01034553 is a clinical study titled "Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma". RATIONALE: Aurora A kinase inhibitor MLN8237 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving aurora A kinase inhibitor MLN8237 together with bortezomib and ...
What is the current status of trial NCT01034553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2010-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01034553?
The interventions under investigation include: bortezomib (DRUG), Aurora A kinase inhibitor MLN8237 (DRUG).
Who is sponsoring clinical trial NCT01034553?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.